Clemence Pouzin

4PUBLICATIONS
10CO-AUTHORS
Molecular targetsCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jan 29, 2026
Novel Drug-Disease Modeling Framework for Oncology Benefit-Risk Evaluation: Application to Tusamitamab Ravtansine.

Marc Cerou, Christine Veyrat-Follet, Sophie Fliscounakis-Huynh

|Nov 15, 2023
Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach.

Clemence Pouzin, Donato Teutonico, Nathalie Fagniez

|Aug 25, 2022
A multi-model approach to predict efficacious clinical dose for an anti-TGF-β antibody (GC2008) in the treatment of osteogenesis imperfecta.

Panteleimon D Mavroudis, Nikhil Pillai, Qingping Wang

|Feb 15, 2022
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.

Clemence Pouzin, Leonid Gibiansky, Nathalie Fagniez

Pageof 1

Frequent Collaborators

1 joint publications

Panteleimon D Mavroudis

1 joint publications

Qingping Wang

1 joint publications

Magalie Pardon

1 joint publications

Sylvie Klieber